A global partnership for next generation therapeutics
FUJIFILM Corporation has announced an investment in VALANX Biotech, a Vienna based biotechnology company developing advanced technologies for antibody drug conjugates.
The investment supports collaboration between FUJIFILM and VALANX to strengthen manufacturing capabilities in this rapidly growing field of biopharmaceuticals. Antibody drug conjugates combine the targeting ability of antibodies with the power of therapeutic drugs. They are designed to deliver treatments directly to diseased cells while reducing side effects. As a result, they are becoming an important class of next generation medicines.
A key challenge in developing these therapies is controlling how and where the drug is attached to the antibody. Small differences can affect stability, safety and treatment effectiveness.
VALANX addresses this challenge with its Golden Site™ technology. The platform enables highly precise attachment points on antibodies by introducing synthetic amino acids at defined positions. This allows drugs to bind at specific locations and in controlled ratios.
The result is improved uniformity and stability of antibody drug conjugates. The technology also opens the door for more predictable manufacturing and better therapeutic performance.
FUJIFILM is actively expanding its capabilities in the ADC field. The company is building a full manufacturing ecosystem that spans antibody production, linker and payload development, conjugation and formulation. A new integrated ADC manufacturing service is expected to launch in Japan in 2027.
Strategic collaborations play an important role in this effort. By partnering with companies that develop breakthrough technologies, FUJIFILM aims to accelerate innovation and support the next wave of biopharmaceutical development.
VALANX is also advancing its own pipeline of drug candidates built on its proprietary platform.
At XISTA Science Ventures, we are proud to support VALANX as part of our portfolio and to see its technology gaining global recognition.
Partnerships like this show how deep science and strong collaboration can help bring new therapies to patients around the world.
Further exciting news from our ecosystem
A global partnership for next generation therapeutics
FUJIFILM Corporation has announced an investment in VALANX Biotech, a Vienna based biotechnology company developing advanced technologies for antibody drug conjugates.
The investment supports collaboration between FUJIFILM and VALANX to strengthen manufacturing capabilities in this rapidly growing field of biopharmaceuticals. Antibody drug conjugates combine the targeting ability of antibodies with the power of therapeutic drugs. They are designed to deliver treatments directly to diseased cells while reducing side effects. As a result, they are becoming an important class of next generation medicines.
A key challenge in developing these therapies is controlling how and where the drug is attached to the antibody. Small differences can affect stability, safety and treatment effectiveness.
VALANX addresses this challenge with its Golden Site™ technology. The platform enables highly precise attachment points on antibodies by introducing synthetic amino acids at defined positions. This allows drugs to bind at specific locations and in controlled ratios.
The result is improved uniformity and stability of antibody drug conjugates. The technology also opens the door for more predictable manufacturing and better therapeutic performance.
FUJIFILM is actively expanding its capabilities in the ADC field. The company is building a full manufacturing ecosystem that spans antibody production, linker and payload development, conjugation and formulation. A new integrated ADC manufacturing service is expected to launch in Japan in 2027.
Strategic collaborations play an important role in this effort. By partnering with companies that develop breakthrough technologies, FUJIFILM aims to accelerate innovation and support the next wave of biopharmaceutical development.
VALANX is also advancing its own pipeline of drug candidates built on its proprietary platform.
At XISTA Science Ventures, we are proud to support VALANX as part of our portfolio and to see its technology gaining global recognition.
Partnerships like this show how deep science and strong collaboration can help bring new therapies to patients around the world.